A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity
Fig 6
Predicted effects of the treatment with seven weekly doses of 24μM of DOX with and without co-treatment with iron chelators.
In the simulation without iron chelator co-treatment (blue), the predicted reduction in the mtDNA content agrees with the experimental data, which was used in the fitting of the model’s parameters [21]. The model was capable of capturing the cardioprotective feature of iron chelator co-treatment (green), and the predicted reduction in the mtDNA content also agrees with experimental data [21]. The model predicts that extending the iron chelation therapy by double (red) or triple (yellow) the duration of the DOX treatment can enhance cardioprotection.